<DOC>
	<DOCNO>NCT02635672</DOCNO>
	<brief_summary>Determine safety , tolerability , pharmacokinetics , maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) BAY 1251152 patient solid tumor aggressive non-hodgkin 's lymphoma ( NHL ) .</brief_summary>
	<brief_title>Phase I Dose Escalation Study BAY 1251152 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Male female patient age &gt; 18 year Patients histologically cytologically confirm solid tumor aggressive NHL refractory exhaust available therapy Adequate bone marrow , liver , renal function Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Active clinically serious infection &gt; Grade 2 Subjects new progressive brain meningeal spinal metastasis . Anticancer chemotherapy immunotherapy study within 4 week prior first dose study drug Major surgery , significant trauma , widefield radiotherapy , therapy monoclonal antibody within 4 week first dose study drug Allogenic bone marrow transplant stem cell rescue within 4 month first dose study drug ; patient must complete immunosuppressive therapy enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Aggressive non-hodgkin 's lymphoma ( NHL )</keyword>
</DOC>